Русский / English
Enter the query
22.03.2016
IMPORT SUBSTITUTION IN ACTION: GRIPPOL® PLUS NOW WITH ANTIGENS PRODUCED IN RUSSIA

Petrovax Pharm is launching production of a state-of-the-art flu vaccine using virus antigens produced in Russia. The Ministry of Health of the Russian Federation has given the green light to start production.

According to Ministry of Health Order 125 of March 21, 2014, vaccines administered to children and pregnant women must be preservative-free. To meet this requirement, Grippol Plus used imported antigens until 2016. In 2015, Russian manufacturers succeeded in producing high-purity antigens with no mercury-containing preservatives. Starting in 2016, the components for Grippol Plus vaccine will be manufactured in accordance with GMP by SPbNIIVS FMBA of Russia in its upgraded facilities.

«Russian research and manufacturing has tremendous potential to create immune therapies that are as good as those produced in Western countries; the antigens that were created at our Institute even surpass their Western equivalents. Working in partnership with NPO Petrovax Pharm was a challenge. The requirements for antigens used in the manufacture of vaccines for children were very strict», said Viktor Truhin, Director of FGUP SPbNIIVS FMBA of Russia.

Every year, NPO Petrovax Pharm produces more than 19 million doses of Grippol Plus vaccine at its plant in the Moscow region. Since 2009, the government has been procuring the vaccine to inoculate pregnant women and infants as young as 6 months in accordance with the National Immunization Schedule.

Russian Minister of Healthcare v. Skvortsova stated that «This vaccine is considered to be one of the best in the world. It is completely safe; we use it to vaccinate pregnant women and infants».